StreetInsider.com News Articles

Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip(TM) Nicotine Patent, Advancing RDT's Global Commercialization Strategy

Thu, 20 Aug 2026 08:30:00 -0400

Second granted nicotine oral-film patent strengthens RDT's intellectual-property portfolio and its collaboration with a global nicotine industry leader, advancing the Company's strategy to build a protected global nicotine delivery platform.

Burlington, Ontario--(Newsfile Corp. - August 20, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in innovative oral thin film drug delivery technology, today announced that, together with its development partner Aavishkar Oral Strips Pvt. Ltd. ("Aavishkar"), have been granted a second key patent covering its QuickStrip™ nicotine oral-film technology.

The Patent Office, Government of India has granted Patent No. 599533, arising

Rapid Dose Therapeutics and Aavishkar Granted Monolayer QuickStrip(TM) Nicotine Patent, Advancing RDT's Global Commercialization Strategy

Thu, 20 Aug 2026 08:30:00 -0400

The Patent Office, Government of India has granted Patent No. 599533, arising

Rapid Dose Therapeutics (DOSE) (RDTCF) and Bodhi Health Expand Distribution and Sales of CurcuWIN(R) QuickStrip(TM) Curcumin Across Canada

Tue, 28 Jul 2026 16:05:00 -0400

Burlington, Ontario--(Newsfile Corp. - July 28, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("Rapid Dose" or "RDT"), a Canadian biotechnology company, and Ontario-based Bodhi Health Inc. ("Bodhi Health") today announced an expansion of their coordinated distribution, sales and market-development efforts for Bodhi Health Sublingual Curcumin, manufactured using Rapid Dose's proprietary QuickStrip™ oral thin-film technology and the patented CurcuWIN® curcumin formulation, with over 300,000 units sold to date.

Rapid Dose produces the oral thin-film product while Bodhi Health serves as the Canadian distributor and North American supplier of the finished CurcuWIN® QuickStrip™ product. The product combines two differentiated technologies:

Rapid Dose Therapeutics (DOSE) (RDTCF) and Bodhi Health Expand Distribution and Sales of CurcuWIN(R) QuickStrip(TM) Curcumin Across Canada

Tue, 28 Jul 2026 16:05:00 -0400

Rapid Dose Therapeutics Extends Strategic Collaboration with Global Nicotine Leader and Initiating Saudi Arabia Commercialization

Tue, 07 Jul 2026 07:00:00 -0400

Burlington, Ontario--(Newsfile Corp. - July 7, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in oral thin film drug delivery technology, is pleased to announce the execution of a Memorandum of Understanding ("MOU") with a global leader in the nicotine products industry, extending the parties' ongoing collaboration surrounding RDT's proprietary QuickStrip™ dissolvable oral nicotine strip technology.

The MOU, executed on June 30, 2026, follows the completion of the previous pre-commercialization development agreement enabling the companies to move seamlessly into the next evolution from pre-commercialization to commercialization of the products ensuring a continuation

Rapid Dose Therapeutics Extends Strategic Collaboration with Global Nicotine Leader and Initiating Saudi Arabia Commercialization

Tue, 07 Jul 2026 07:00:00 -0400

Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets

Mon, 13 Apr 2026 09:51:00 -0400

Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities.

The upgrade program is focused on advancing the facility toward compliance with Health Canada Drug Establishment Licence (DEL) requirements, a critical regulatory pathway for companies engaged in the manufacturing, packaging, testing, distribution, and commercialization of pharmaceutical products in Canada. These enhancements

Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets

Mon, 13 Apr 2026 09:51:00 -0400

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Mon, 06 Apr 2026 16:30:00 -0400

Burlington, Ontario--(Newsfile Corp. - April 6, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on March 31, 2026. The Company expects to issue the Common Shares no later than April 15, 2026.

The Notes were issued as a result of an extension to the promissory notes that were originally issued by the Company pursuant to its private placement

Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Mon, 06 Apr 2026 16:30:00 -0400

The Notes were issued as a result of an extension to the promissory notes that were originally issued by the Company pursuant to its private placement

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory

Thu, 26 Mar 2026 09:09:00 -0400

Burlington, Ontario--(Newsfile Corp. - March 26, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology leader specializing in innovative oral thin film drug delivery, is pleased to provide shareholders with a strategic update highlighting its continued execution, operational resilience, and expanding global footprint.

In an environment marked by global market volatility and geopolitical uncertainty, RDT is uniquely positioned with a business model that remains largely insulated from external disruptions. The Company's operations are not dependent on oil-linked inputs or global shipping constraints, and its cost structure is primarily composed of stable, fixed components.

Rapid Dose Therapeutics Reinforces Strategic Strength and Global Growth Trajectory

Thu, 26 Mar 2026 09:09:00 -0400

Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market

Thu, 05 Mar 2026 10:08:00 -0400

Burlington, Ontario--(Newsfile Corp. - March 5, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Nicotine Bilayer Oral Film in partnership with Aavishkar Oral Strips.

The patent, titled "Nicotine Bilayer Oral Film and Process for Preparation Thereof," has been granted by the Indian Patent Office under Patent Number IN 582202, based on Patent Application No. IN 202441055689 filed July 22, 2024 under the Patent Cooperation Treaty (PCT) framework.

The patent covers Rapid Dose Therapeutics' bilayer oral thin film

Rapid Dose Therapeutics (DOSE) (RDTCF) Secures Patent for QuickStrip(TM) Nicotine Oral Film Targeting $38B Smoke-Free Nicotine Market

Thu, 05 Mar 2026 10:08:00 -0400

The patent covers Rapid Dose Therapeutics' bilayer oral thin film

Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform

Mon, 23 Feb 2026 06:12:00 -0400

Burlington, Ontario--(Newsfile Corp. - February 23, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company focused on innovative drug delivery solutions, today provided an update on its ongoing cannabinoid research initiatives and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform.

Independent research led by colleagues Dr. Patrick Neary of the Faculty of Kinesiology & Health Studies at the University of Regina and Dr. Jane Alcorn of the College of Pharmacy & Nutrition at the

Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip(TM) Platform

Mon, 23 Feb 2026 06:12:00 -0400

Independent research led by colleagues Dr. Patrick Neary of the Faculty of Kinesiology & Health Studies at the University of Regina and Dr. Jane Alcorn of the College of Pharmacy & Nutrition at the

Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors

Wed, 11 Feb 2026 11:21:00 -0400

Burlington, Ontario--(Newsfile Corp. - February 11, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced that its common shares are now trading in the United States on the OTCQB Venture Market under the ticker symbol RDTCF.

The OTCQB listing expands Rapid Dose Therapeutics' presence in the U.S. capital markets by increasing accessibility and visibility for American investors while providing direct access to the company's shares, enhancing liquidity, broadening market participation, and strengthening engagement with the North American life sciences investment community.

"Trading on the OTCQB strengthens our visibility

Rapid Dose Therapeutics Begins Trading on the OTCQB in the United States Under Symbol RDTCF, Expanding Access for U.S. Healthcare and Biotechnology Investors

Wed, 11 Feb 2026 11:21:00 -0400

"Trading on the OTCQB strengthens our visibility

Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment

Tue, 10 Feb 2026 07:00:00 -0400

Burlington, Ontario--(Newsfile Corp. - February 10, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") , a Canadian biotechnology company focused on innovative drug delivery solutions, today announced the commercial launch of its Entourage Phytolab co-branded QuickStrip™ medical cannabis oral thin film in Brazil following regulatory approval for both manufacturing and distribution by Brazil's National Health Regulatory Agency (ANVISA).

This milestone positions RDT among the first companies to introduce an oral dissolvable strip medical cannabis product to Brazil's healthcare market.

Brazil is poised to become one of the largest producers of medicinal cannabis worldwide with the adoption

Rapid Dose Therapeutics Launches QuickStrip(TM) Medical Cannabis for Patients in Brazil following ANVISA Approval of Sublingual and Buccal Formats for Medical Treatment

Tue, 10 Feb 2026 07:00:00 -0400

This milestone positions RDT among the first companies to introduce an oral dissolvable strip medical cannabis product to Brazil's healthcare market.

Brazil is poised to become one of the largest producers of medicinal cannabis worldwide with the adoption